New Study Data, Campaigns, and Status Updates Announced in the Q1 2026 Gastric and Esophageal Cancers Market

AstraZeneca and Daiichi Sankyo touted Enhertu’s availability in Japan and presented updates on their financial results and portfolios.

Accord launched a new physician-directed campaign for Hercessi.

AstraZeneca announced Imfinzi’s European approval for a new indication and offered updates on its financial results and portfolio.

Amgen discussed its work, portfolio, and pipeline, highlighting its biosimilar products like Kanjinti.

Press releases promoted new efficacy results for Tevimbra plus Ziihera. Zymeworks and Jazz Pharmaceuticals also noted their participation in conferences, 2025 milestones, and 2026 goals.

Pfizer, which marketed Trazimera, advertised its updated Pfizer Oncology Together site.

Astellas discussed updates to its financial results and portfolio, noting Vyloy’s place within its marketing strategy.